Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23132428 | 0.84 | HCAR2 (0.49) | NOTUMALDH1A1PTPN1HCAR2FDPS | |
| SCHEMBL1810164 | 0.83 | SMN1; SMN2 (0.44) | ALDH1A1PTPN1FDPSHDAC6HPGD | |
| SCHEMBL5987816 | 0.81 | ALDH1A1 (0.44) | ALDH1A1PTPN1FDPSHDAC6MAPT | |
| SCHEMBL1805432 | 0.81 | PTPN1 (0.44) | ALDH1A1PTPN1HCAR2FDPSHDAC6 | |
| SCHEMBL14538015 | 0.81 | ALDH1A1 (0.44) | ALDH1A1PTPN1HCAR2FDPSHDAC6 | |
| SCHEMBL345666 | 0.81 | NOTUM (0.43) | NOTUMALDH1A1HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL2131964 | 0.81 | TP53 (0.50) | ALDH1A1PTPN1HCAR2FDPSMAPT | |
| SCHEMBL3823349 | 0.81 | NOTUM (0.47) | NOTUMALDH1A1PTPN1HCAR2FDPS | |
| SCHEMBL2328124 | 0.81 | NOTUM (0.43) | NOTUMALDH1A1HDAC6MAPTHPGD | |
| SCHEMBL6370697 | 0.81 | PTPN1 (0.46) | ALDH1A1PTPN1HCAR2FDPSHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171346-A1 | Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S.A. (FR) | 2005-08-04 | — | — | US | claimed |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | REMYND N.V. (BE) | 2024-12-31 | — | — | US | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2024-03-26 | — | — | US | disclosed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | disclosed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | disclosed |
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-110650955-B | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | 瑞敏德股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-30 | — | — | US | disclosed |
| US-7795254-B2 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2220078-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | Amgen, Inc (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010089510-A2 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010055267-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-05-20 | — | — | WO | disclosed |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2009058267-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-7034022-B2 | Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S. A. (FR) | 2006-04-25 | — | — | US | disclosed |
| US-20050171346-A1 | Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S.A. (FR) | 2005-08-04 | — | — | US | disclosed |
| US-5464860-A | Antiepileptic agents | NOVAPHARME (FR) | 1995-11-07 | — | — | US | disclosed |
| US-5258397-A | FOR TREATMENT OF EPILEPSY; SIDE EFFECT REDUCTION | NOVAPHARME (FR) | 1993-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | BDKRB2, BDKRB1, OPRK1 | NOTUM 1857/4885ALDH1A1 1048/4885PTPN1 2587/4885 |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | PDE4A, PDE12, PDE2A | NOTUM 2205/4885ALDH1A1 1375/4885PTPN1 3263/4885 |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | MAPT, PSEN1, PSEN2 | NOTUM 1671/4885ALDH1A1 1030/4885PTPN1 4468/4885 |
| US-20050171346-A1 | Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation | HEXD, CDK5, CHUK | NOTUM 1376/4885ALDH1A1 454/4885PTPN1 1016/4885 |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | MAPT, PSEN1, PSEN2 | NOTUM 1671/4885ALDH1A1 1030/4885PTPN1 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.